Neoantigen Vaccine Development for Bladder Cancer
Recently, significant advancements in neoantigen research have greatly expedited the progress and regulatory approval of tumor immunotherapies, encompassing cancer vaccines. At Alfa Cytology, our expertise lies in the development of cutting-edge neoantigen vaccines that effectively stimulate the immune system to specifically target bladder cancer neoantigens, thereby presenting a highly promising avenue.
Introduction to Neoantigen Vaccine
Neoantigens are recently formed antigens produced by tumor cells due to multiple tumor-specific alterations, such as genomic mutations, aberrant RNA splicing, disrupted post-translational modifications, and integrated viral open reading frames. Neoantigens are recognized as foreign entities and trigger an immune response that is capable of evading central and peripheral tolerance mechanisms.
The advanced development of next-generation sequencing and bioinformatic technologies has facilitated the rapid identification and prediction of tumor-specific neoantigens. In comparison to tumor-associated antigens, these neoantigens possess a high level of immunogenicity and specificity towards tumors, making them promising targets for personalized cancer immunotherapies. Neoantigens are identified and validated to create personalized vaccines that stimulate a robust immune response against cancer cells. This tailored approach aims to improve the precision and efficacy of cancer treatments.
Fig.1 Synthesis of neoantigen. (Zhang, Z., et al., 2021)
Our Services
Our neoantigen vaccine development service for bladder cancer encompasses a comprehensive and meticulous workflow, specifically designed to identify, validate, and utilize neoantigens to create tailored vaccines. This service is strategically crafted to advance your research and therapeutic development with utmost precision and efficiency.
Neoantigen Identification and Selection
- Genomic and Transcriptomic Analysis
We perform thorough genomic and transcriptomic analyses to identify tumor-specific mutations.
- Bioinformatics Analysis
Our robust bioinformatics analysis predicts potential neoantigens by analyzing tumor-specific mutations and their binding affinity to MHC molecules.
Neoantigen Validation
- In Silico Validation
Computational tools are employed to prioritize candidate neoantigens based on their immunogenic potential.
- In Vitro Validation
We conduct various in vitro assays to validate the immunogenicity of the predicted neoantigens, ensuring their effectiveness in eliciting an immune response.
Vaccine Design and Production
- Peptide Synthesis
Custom peptides corresponding to validated neoantigens are synthesized for vaccine formulation.
- Vaccine Formulation
We develop vaccine formulations with optimized adjuvants to enhance the immune response and improve vaccine efficacy.
Preclinical Evaluation
- In Vivo Studies
Our preclinical models are used to evaluate the safety and efficacy of neoantigen vaccines, assessing tumor growth inhibition and immune response.
- Immune Monitoring
Comprehensive immune monitoring is conducted to ensure the vaccine elicits a robust and specific anti-tumor response.
Contact Us
Equipped with state-of-the-art technology platforms and a team of highly skilled scientific professionals, Alfa Cytology has amassed extensive expertise in the development of neoantigen vaccines. We are delighted to offer our cutting-edge technology and vast knowledge in neoantigen vaccine development for Bladder Cancer to support our clients' related project endeavors. For further information, please do not hesitate to contact us.
Reference
- Zhang, Z., Lu, M., and et al. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Frontiers in immunology, 2021, 12, 672356.
For research use only. Not intended for any clinical use.
Related Services
